FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHA Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor [NCT06065540]RESEARCHSemaglutide in Alcohol Use Disorder [NCT07949474]RESEARCHEffects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease [NCT06409130]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]NEWS‘Selling and marketing snake oil’: The debate over compounded GLP-1sRESEARCHSemaglutide Effects on Sperm Concentration in Overweight Infertile Men [NCT07946796]RESEARCHTirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension [NCT07946315]

研究用のみ。 完全な免責事項 →

研究/Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.
研究ライブラリに戻る
tirzepatideGIP receptor agonistGLP-1 receptor agonist

Highlighting the potential of tirzepatide as a novel dual GIP and GLP-1 receptor agonist for managing type 2 diabetes, focusing on its efficacy and safety profile.

May 17, 2026
Share

元の論文

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock Julio et al.Lancet (London, England)2021
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、上記の元の論文から得られた見解をペプチド研究コミュニティ向けに読みやすく分解しています。私たちの目標は、最も重要な点 — 実践的な意味合い、証拠の強さ、そして継続的研究に対する影響 — を強調することです。

Novel Dual GIP and GLP-1 Receptor Agonist Shows Promise in Type 2 Diabetes Management

Published: May 17, 2026 | Source: Lancet (London, England) (2021) | Category: tirzepatide, GIP receptor agonist, GLP-1 receptor agonist

Overview

A recent study published in the Lancet has shown that a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist called tirzepatide can significantly improve glycemic control and body weight in patients with type 2 diabetes who are not adequately managed by diet and exercise alone. This research highlights the potential of this new class of drugs for managing a condition that affects millions globally.

Study Background

Type 2 diabetes is a chronic illness characterized by high blood sugar levels due to insulin resistance or insufficient insulin production. Despite advancements in treatment, many patients struggle to achieve optimal glycemic control with existing therapies. The development of tirzepatide aims to address this gap by targeting both GIP and GLP-1 receptors, which are involved in glucose regulation and weight management.

What the Research Found

The SURPASS-1 trial was a 40-week, double-blind, randomized, placebo-controlled phase 3 study conducted across multiple countries. Participants were adults with type 2 diabetes inadequately controlled by diet and exercise alone who had not previously used injectable diabetes therapies. They were randomly assigned to receive once-weekly doses of tirzepatide (5 mg, 10 mg, or 15 mg) or placebo.

The primary outcome was the mean change in glycated hemoglobin (HbA1c), a measure of long-term blood sugar control. The study found that all three doses of tirzepatide led to significant reductions in HbA1c compared to placebo. Additionally, participants treated with tirzepatide experienced substantial weight loss and showed no increased risk of hypoglycaemia.

What This Means for Peptide Users

The results suggest that tirzepatide could be a promising new option for patients who have not responded well to traditional diabetes management strategies. Its dual mechanism of action targeting both GIP and GLP-1 receptors may offer enhanced efficacy in improving glycemic control and body weight, which are critical factors in managing type 2 diabetes.

Limitations and Caveats

While the study demonstrated significant benefits with tirzepatide, it had several limitations. The trial's relatively short duration of 40 weeks means that long-term safety and efficacy remain uncertain. Additionally, the exclusion of patients already on injectable therapies limits the generalizability of these findings to a broader patient population.

How This Compares to Previous Research

Previous studies have focused primarily on GLP-1 receptor agonists alone for type 2 diabetes management. The introduction of tirzepatide represents an advancement by targeting both GIP and GLP-1 receptors, potentially offering superior therapeutic effects compared to single-receptor agonists.

Our Analysis

The SURPASS-1 trial provides compelling evidence for the efficacy and safety profile of tirzepatide as a novel dual receptor agonist in type 2 diabetes management. However, further research is needed to confirm its long-term benefits and assess its suitability across diverse patient populations, including those already on injectable therapies.

Key Takeaways

  • Efficacy: Tirzepatide showed significant improvements in glycemic control and body weight compared to placebo.
  • Safety: The drug demonstrated a safety profile consistent with GLP-1 receptor agonists without increased hypoglycaemia risk.
  • Limitations: Short study duration and exclusion of patients on injectable therapies limit broader applicability.

Original Source

Citation: Rosenstock Julio, Wysham Carol, Frías Juan P et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.. Lancet (London, England). DOI: 10.1016/S0140-6736(21)01324-6

Access:

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

編集者の注

この分析はPeptide Contacts研究チームによって作成されました。情報確認のために常に元のソースをご確認ください。 元の論文 詳細な方法論とデータについては 元の出版物は以下で利用可能です PubMed.

関連研究

Comments

Sign in to join the discussion

この分析は査読済みの研究から生成され、教育目的のみで使用されます。医療アドバイスにはなりません。ペプチドベースの治療を使用する前に常に格付けされた医療専門家に相談してください。